APO RESEARCH · REPORT
Respiratory Distress Syndrome
Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
Product & engineering
Understand the product.
Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
Selected research
Industry Research
Respiratory Distress Syndrome Industry Research Report 2026
Market perspective
Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.
Report Scope
Read the full market overview
This report quantifies the global Respiratory Distress Syndrome market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Respiratory Distress Syndrome.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Respiratory Distress Syndrome Market by Company
Chiesi Farmaceutici
CR-Double Crane
ONY Biotech
AbbVie
Yuhan Corporation
JW Pharmaceuticals
Noargen
Respiratory Distress Syndrome Segment by Type
Poractant Alfa
Beractant
Calfactant
Others
Respiratory Distress Syndrome Segment by Application
Very Preterm Infants
Moderate to Late Preterm Infants
Others
Respiratory Distress Syndrome Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Distress Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Distress Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Distress Syndrome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Respiratory Distress Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Poractant Alfa
- Beractant
- Calfactant
- Others
Applications
- Very Preterm Infants
- Moderate to Late Preterm Infants
- Others
Companies covered
- Chiesi Farmaceutici
- CR-Double Crane
- ONY Biotech
- AbbVie
- Yuhan Corporation
- JW Pharmaceuticals
- Noargen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Respiratory Distress Syndrome by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Poractant Alfa
- 2.2.3 Beractant
- 2.2.4 Calfactant
- 2.2.5 Others
- 2.3 Respiratory Distress Syndrome by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Very Preterm Infants
- 2.3.3 Moderate to Late Preterm Infants
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Respiratory Distress Syndrome Breakdown Data by Type
- 3.1 Global Respiratory Distress Syndrome Historic Market Size by Type (2021-2026)
- 3.2 Global Respiratory Distress Syndrome Forecasted Market Size by Type (2027-2032)
4 Respiratory Distress Syndrome Breakdown Data by Application
- 4.1 Global Respiratory Distress Syndrome Historic Market Size by Application (2021-2026)
- 4.2 Global Respiratory Distress Syndrome Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Respiratory Distress Syndrome Market Perspective (2021-2032)
- 5.2 Global Respiratory Distress Syndrome Growth Trends by Region
- 5.2.1 Global Respiratory Distress Syndrome Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Respiratory Distress Syndrome Historic Market Size by Region (2021-2026)
- 5.2.3 Respiratory Distress Syndrome Forecasted Market Size by Region (2027-2032)
- 5.3 Respiratory Distress Syndrome Market Dynamics
- 5.3.1 Respiratory Distress Syndrome Industry Trends
- 5.3.2 Respiratory Distress Syndrome Market Drivers
- 5.3.3 Respiratory Distress Syndrome Market Challenges
- 5.3.4 Respiratory Distress Syndrome Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Respiratory Distress Syndrome Players by Revenue
- 6.1.1 Global Top Respiratory Distress Syndrome Players by Revenue (2021-2026)
- 6.1.2 Global Respiratory Distress Syndrome Revenue Market Share by Players (2021-2026)
- 6.2 Global Respiratory Distress Syndrome Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Respiratory Distress Syndrome Head Office and Area Served
- 6.4 Global Respiratory Distress Syndrome Players, Product Type & Application
- 6.5 Global Respiratory Distress Syndrome Manufacturers Established Date
- 6.6 Global Respiratory Distress Syndrome Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Respiratory Distress Syndrome Market Size (2021-2032)
- 7.2 North America Respiratory Distress Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Respiratory Distress Syndrome Market Size by Country (2021-2026)
- 7.4 North America Respiratory Distress Syndrome Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Respiratory Distress Syndrome Market Size (2021-2032)
- 8.2 Europe Respiratory Distress Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Respiratory Distress Syndrome Market Size by Country (2021-2026)
- 8.4 Europe Respiratory Distress Syndrome Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Respiratory Distress Syndrome Market Size (2021-2032)
- 9.2 Asia-Pacific Respiratory Distress Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Respiratory Distress Syndrome Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Respiratory Distress Syndrome Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Respiratory Distress Syndrome Market Size (2021-2032)
- 10.2 South America Respiratory Distress Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Respiratory Distress Syndrome Market Size by Country (2021-2026)
- 10.4 South America Respiratory Distress Syndrome Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Respiratory Distress Syndrome Market Size (2021-2032)
- 11.2 Middle East & Africa Respiratory Distress Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Respiratory Distress Syndrome Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Respiratory Distress Syndrome Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Chiesi Farmaceutici
- 12.1.1 Chiesi Farmaceutici Company Information
- 12.1.2 Chiesi Farmaceutici Business Overview
- 12.1.3 Chiesi Farmaceutici Revenue in Respiratory Distress Syndrome Business (2021-2026)
- 12.1.4 Chiesi Farmaceutici Respiratory Distress Syndrome Product Portfolio
- 12.1.5 Chiesi Farmaceutici Recent Developments
- 12.2 CR-Double Crane
- 12.2.1 CR-Double Crane Company Information
- 12.2.2 CR-Double Crane Business Overview
- 12.2.3 CR-Double Crane Revenue in Respiratory Distress Syndrome Business (2021-2026)
- 12.2.4 CR-Double Crane Respiratory Distress Syndrome Product Portfolio
- 12.2.5 CR-Double Crane Recent Developments
- 12.3 ONY Biotech
- 12.3.1 ONY Biotech Company Information
- 12.3.2 ONY Biotech Business Overview
- 12.3.3 ONY Biotech Revenue in Respiratory Distress Syndrome Business (2021-2026)
- 12.3.4 ONY Biotech Respiratory Distress Syndrome Product Portfolio
- 12.3.5 ONY Biotech Recent Developments
- 12.4 AbbVie
- 12.4.1 AbbVie Company Information
- 12.4.2 AbbVie Business Overview
- 12.4.3 AbbVie Revenue in Respiratory Distress Syndrome Business (2021-2026)
- 12.4.4 AbbVie Respiratory Distress Syndrome Product Portfolio
- 12.4.5 AbbVie Recent Developments
- 12.5 Yuhan Corporation
- 12.5.1 Yuhan Corporation Company Information
- 12.5.2 Yuhan Corporation Business Overview
- 12.5.3 Yuhan Corporation Revenue in Respiratory Distress Syndrome Business (2021-2026)
- 12.5.4 Yuhan Corporation Respiratory Distress Syndrome Product Portfolio
- 12.5.5 Yuhan Corporation Recent Developments
- 12.6 JW Pharmaceuticals
- 12.6.1 JW Pharmaceuticals Company Information
- 12.6.2 JW Pharmaceuticals Business Overview
- 12.6.3 JW Pharmaceuticals Revenue in Respiratory Distress Syndrome Business (2021-2026)
- 12.6.4 JW Pharmaceuticals Respiratory Distress Syndrome Product Portfolio
- 12.6.5 JW Pharmaceuticals Recent Developments
- 12.7 Noargen
- 12.7.1 Noargen Company Information
- 12.7.2 Noargen Business Overview
- 12.7.3 Noargen Revenue in Respiratory Distress Syndrome Business (2021-2026)
- 12.7.4 Noargen Respiratory Distress Syndrome Product Portfolio
- 12.7.5 Noargen Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst